- Report
- January 2026
- 196 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- February 2026
- 250 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- February 2026
- 250 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- May 2026
- 191 Pages
Global
From €5135EUR$5,850USD£4,441GBP
- Report
- October 2025
- 160 Pages
Global
From €2947EUR$3,358USD£2,549GBP
€3467EUR$3,950USD£2,999GBP
- Report
- October 2025
- 160 Pages
Global
From €2947EUR$3,358USD£2,549GBP
€3467EUR$3,950USD£2,999GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,272USD£3,133GBP
- Report
- August 2025
- 180 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- May 2026
- 291 Pages
Global
From €5135EUR$5,850USD£4,441GBP
- Report
- July 2025
- 155 Pages
Global
From €4081EUR$4,650USD£3,530GBP
- Report
- May 2025
- 150 Pages
Global
From €5222EUR$5,950USD£4,517GBP
- Report
- January 2026
- 197 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- January 2026
- 194 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- January 2026
- 182 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- January 2026
- 191 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- January 2026
- 199 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- January 2026
- 198 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- January 2026
- 193 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- January 2026
- 184 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP
- Report
- January 2026
- 193 Pages
Global
From €3112EUR$3,545USD£2,691GBP
€3457EUR$3,939USD£2,990GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more